EyePoint Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of Directors: Fred Hassan

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Fred Hassan”): 54,312,641 for, 472,033 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2026 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 16,244,833 for, 6,929 withheld.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 43 managers: 16,048,123 for, 202,822 withheld. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1 managers: 1,481,977 for.

Description as filed by funds: Election of Directors: Jay S. Duker, M.D.

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jay S. Duker, M.D.”): 54,378,788 for, 405,886 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2026 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 99.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 16,244,833 for, 6,929 withheld.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Description as filed by funds: Election of Directors: John B. Landis, Ph.D.

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: John B. Landis, Ph.D.”): 52,869,736 for, 1,914,938 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2026 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 16,056,060 for, 195,702 withheld.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Description as filed by funds: Election of Directors: Karen Zaderej

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Karen Zaderej”): 54,145,995 for, 638,679 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2026 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 16,244,551 for, 7,211 withheld.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Description as filed by funds: Election of Directors: Nancy Lurker

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Nancy Lurker”): 52,749,972 for, 2,034,702 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2026 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 16,056,060 for, 195,702 withheld.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Description as filed by funds: Election of Directors: Reginald Sanders, M.D.

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Reginald J. Sanders, M.D.”): 54,578,010 for, 206,664 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2026 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 16,244,833 for, 6,929 withheld.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Description as filed by funds: Election of Directors: Stuart Duty

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Stuart Duty”): 54,213,405 for, 571,269 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2026 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 16,244,551 for, 7,211 withheld.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Description as filed by funds: Election of Directors: Wendy DiCicco

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Wendy F. DiCicco”): 53,886,305 for, 898,369 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2026 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 16,244,551 for, 7,211 withheld.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Description as filed by funds: To approve Amendment No. 2 to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 2,900,000 shares.

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“2. Amendment to 2023 Long-Term Incentive Plan”): 41,319,557 for, 13,015,428 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Amendment to 2023 Long-Term Incentive Plan The Company's stockholders approved the 2023 Plan Amendment to increase the number of shares of Common Stock authorized for issuance thereunder by 2,900,000 shares.”
Support: 76% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 45 managers: 14,259,265 for, 2,072,809 against, 6,929 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 2 managers: 1,481,977 for, 39 against.

Description as filed by funds: To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“3. Non-Binding Advisory Vote on Named Executive Officer Compensation”): 50,767,710 for, 3,552,037 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Non-Binding Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 45 managers: 15,229,874 for, 1,102,200 against, 6,929 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 151 managers: 43,778,241 for, 3,034,670 against, 71 not voted, 21,896 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 44 managers: 40,928 for, 6,929 abstained, 16,200,544 1 year, 3,361 3 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 141 managers: 5,893,956 for, 394 against, 71 not voted, 33,904,362 1 year, 11,208 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“5. Ratification of Appointment of Independent Registered Public Accounting Firm”): 60,529,812 for, 118,502 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 45 managers: 16,331,768 for, 306 against, 6,929 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1 managers: 1,481,977 for.